Quest Diagnostics Inc  (DGX)
Other Ticker:  
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
Price: $127.0514 $0.07 0.056%
Day's High: $127.3225 Week Perf: -1.15 %
Day's Low: $ 127.05 30 Day Perf: -0.96 %
Volume (M): 11 52 Wk High: $ 148.62
Volume (M$): $ 1,452 52 Wk Avg: $132.53
Open: $127.62 52 Wk Low: $119.59

 Market Capitalization (Millions $) 14,486
 Shares Outstanding (Millions) 114
 Employees 49,000
 Revenues (TTM) (Millions $) 9,252
 Net Income (TTM) (Millions $) 908
 Cash Flow (TTM) (Millions $) 371
 Capital Exp. (TTM) (Millions $) 408

Quest Diagnostics Inc
We are the nations leading provider of diagnostic testing, information and related services, providing insights that enable physicians, hospitals, managed care organizations and other healthcare professionals to make decisions to improve health. We offer patients and physicians the broadest access to diagnostic laboratory services through our national network of laboratories and patient service centers. We provide interpretive consultation through the largest medical and scientific staff in the industry, with over 300 physicians and Ph.D.s around the country. We are the leading provider of esoteric testing, including gene-based testing, and testing for drugs of abuse. We are also a leading provider of anatomic pathology services and testing for clinical trials.
We empower healthcare organizations and clinicians with state-of-the-art information technology solutions that can improve practice management and patient care.

   Company Address: 500 Plaza Drive Secaucus, 7094 NJ
   Company Phone Number: 520-2700   Stock Exchange / Ticker: NYSE DGX

Customers Net Income grew by DGX's Customers Net Profit Margin fell to

5.29 %

2.74 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
LH   -3.18%    
NEO   -5.79%    
• View Complete Report

Quest Diagnostics Inc

Quest Diagnostics Inc defies expectations with a surge in earnings per share despite a decline in revenue

In the financial fourth quarter of 2023, Quest Diagnostics Inc (DGX) reported a decrease in revenue but managed to raise its earnings per share, showing positive growth in its income per share. Despite a decline in revenue by -1.929% to $2.29 billion year on year, income per share surged by 91.92% to $1.68 per share. This marks a decrease from the previous reporting period where profits fell from $1.96 per share and revenue decreased by -0.305% from $2.30 billion.
Net income also saw a significant increase in the financial fourth quarter of 2023, rising by 76.72% to $205.000 million from $116.000 million reported in the same quarter a year ago. Quest Diagnostics Inc also highlighted its improving profit margins, with net margin rising to 8.96% and operating margin edging up to 11.67%. Despite an increase in stockpiles to $190.0 million due to seasonal factors, they remain below the previous year's level of $192.0 million. Operating earnings also showed growth, rising by 97.78% to $267 million.

Product Service News

Quest Diagnostics and Ultima Genomics Forge Groundbreaking Partnership to Revolutionize Oncology and Clinical Diagnostics

Published Tue, Jan 9 2024 1:05 PM UTC

Quest Diagnostics and Ultima Collaborate to Revolutionize Oncology and Clinical Diagnostics with Next-Generation Sequencing TechnologyIn a groundbreaking partnership, Quest Diagnostics, the leading provider of diagnostic information services, and Ultima Genomics, the developer of an innovative ultra-high throughput sequencing architecture, have joined forces to accelerate th...

Quest Diagnostics Inc

Quest Diagnostics Inc. Reports Decline in Financial Performance for Fiscal Q3 2023

Quest Diagnostics Inc, one of the leading medical laboratories in the industry, reported a decline in its bottom-line and income per share for the July to September 30, 2023 interval. The bottom-line decreased by 9.68% to $1.96 per share compared to $2.17 per share in the same period a year ago, while income per share decreased by 4.39% from $2.05 per share in the previous reporting period.
These disappointing results were mirrored in the company's revenue, which decreased by 7.683% to $2.30 billion from $2.49 billion in the comparable reporting period last year. Sequentially, the revenue declined by 1.839% from $2.34 billion. It is important to note that this deterioration in revenue is in stark contrast to the overall trend in the Medical Laboratories industry, which experienced a top-line rise during the same period.
Furthermore, Quest Diagnostics Inc's earnings for the July to September 30, 2023 interval also suffered, falling by 14.13% to $237 million compared to $276 million in the corresponding period a year ago. This decline in earnings contributed to the decrease in profitability, with the operating margin decreasing to 14.9% and the net margin shrinking to 10.33%.

Quest Diagnostics Inc

Quest Diagnostics Masks Revenue Dip with Impressive Earnings: Sees Minor Decline but Delivers 4.59% EPS Growth as Industry Thrives

Quest Diagnostics Inc, a leading provider of diagnostic testing services, recently released its financial results for the fiscal second quarter of 2023. Despite facing soft demand during this period, the company managed to improve its earnings per share (EPS) by 4.59% to $2.05 per share. However, revenue experienced a decline of -4.688% to $2.34 billion compared to the same period last year.
In contrast to Quest Diagnostics Inc, the rest of the Medical Laboratories industry recorded a revenue improvement during the second quarter of 2023. Looking at the results from the previous reporting period, revenue surged by 0.3% from $2.33 billion, and EPSS increased by 15.17% from $1.78 per share. Unfortunately, net profits fell slightly by -0.4% to $249.000 million in the fiscal second quarter of 2023, compared to $250.000 million in the corresponding period a year before.

Quest Diagnostics Inc

Serious revenue drop, at the company in the financial three months ending March 31 2023

Quest Diagnostics Inc. is a leading diagnostic testing and information services company with a reputation for delivering high-quality services to patients, physicians, hospitals, and other diagnostic providers. The company offers a broad range of diagnostic testing services, including routine and specialty testing, clinical and anatomic pathology, and toxicology testing. As one of the largest clinical laboratories in the United States, Quest Diagnostics Inc. serves millions of patients every year through its extensive network of more than 2,200 patient service centers and over 220 logistics locations throughout the country.
Recent Financial Performance
In the first quarter of 2023, Quest Diagnostics Inc. announced a decline in top and bottom-line results as compared to the same period in the previous year. The company's revenue dropped by 10.724%, falling to $2.33 billion from $2.61 billion in the first quarter of 2022. Similarly, earnings per share (EPS) declined sharply by 39.04% to $1.78 from $2.92 in the preceding year's first quarter. Despite this decline, Quest Diagnostics Inc. has experienced rapid growth in earnings per share, which has grown by 102.96% from $0.88 per share in the previous period.


Quest Diagnostics Inc's Segments
Clinical laboratory testing business
 Segment     of total Revenue
All other operating segments
 Segment     of total Revenue
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com